In the analyses that included all the participants (regardless of diabetes status), the use of SGLT2 inhibitors was associated with significantly reduced risk of all-cause mortality (HR = 0.83, 95% CI, 0.75–0.91; I2 0%) (Figure 1), hospitalisation for heart failure (HHF) (HR = 0.68, 95% CI, 0.61–0.75; I2 0%) (Figure 2), CV death (HR = 0.82, 95% CI, 0.74–0.92; I2 0%) (Figure 3), and hospitalisation for heart failure or CV death (HR = 0.72, 95% CI, 0.66–0.78; I2 0%) (Figure 4) compared with placebo. Here, SLC5A2 is linked to diabetes mellitus.